» Articles » PMID: 33841143

Medicinal Plants in COVID-19: Potential and Limitations

Overview
Journal Front Pharmacol
Date 2021 Apr 12
PMID 33841143
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Currently, the search to identify treatments and vaccines for novel coronavirus disease (COVID-19) are ongoing. Desperation within the community, especially among the middle-and low-income groups acutely affected by the economic impact of forced lockdowns, has driven increased interest in exploring alternative choices of medicinal plant-based therapeutics. This is evident with the rise in unsubstantiated efficacy claims of these interventions circulating on social media. Based on enquiries received, our team of researchers was given the chance to produce evidence summaries evaluating the potential of complementary interventions in COVID-19 management. Here, we present and discuss the findings of four selected medicinal plants (, , , ), with reported antiviral, anti-inflammatory, and immunomodulatory effects that might be interesting for further investigation. Our findings showed that only reported positive antiviral evidence specific to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on preliminary data while all four medicinal plants demonstrated differential anti-inflammatory or immunomodulatory effects. The definitive roles of these medicinal plants in cytokine storms and post-infection complications remains to be further investigated. Quality control and standardisation of medicinal plant-based products also needs to be emphasized. However, given the unprecedented challenges faced, ethnopharmacological research should be given a fair amount of consideration for contribution in this pandemic.

Citing Articles

The efficacy of herbal medicines on the length of stay and negative conversion time/rate outcomes in patients with COVID-19: a systematic review.

Latarissa I, Meiliana A, Sormin I, Sugiono E, Wathoni N, Barliana M Front Pharmacol. 2024; 15:1383359.

PMID: 38873430 PMC: 11169809. DOI: 10.3389/fphar.2024.1383359.


Phytobioactive compounds as therapeutic agents for human diseases: A review.

Riaz M, Khalid R, Afzal M, Anjum F, Fatima H, Zia S Food Sci Nutr. 2023; 11(6):2500-2529.

PMID: 37324906 PMC: 10261751. DOI: 10.1002/fsn3.3308.


Natural Products as a Potential Source of Promising Therapeutics for COVID-19 and Viral Diseases.

Bafandeh S, Khodadadi E, Ganbarov K, Asgharzadeh M, Kose S, Kafil H Evid Based Complement Alternat Med. 2023; 2023:5525165.

PMID: 37096202 PMC: 10122587. DOI: 10.1155/2023/5525165.


The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies among staff and students in a Cameroon University.

Wondeu A, Talom B, Linardos G, Ngoumo B, Bello A, Ndassi Soufo A J Public Health Afr. 2023; 14(1):2242.

PMID: 36798849 PMC: 9926561. DOI: 10.4081/jphia.2023.2242.


Pharmacological Activities of Fingerroot Extract and Its Phytoconstituents Against SARS-CoV-2 Infection in Golden Syrian Hamsters.

Kongratanapasert T, Kongsomros S, Arya N, Sutummaporn K, Wiriyarat W, Akkhawattanangkul Y J Exp Pharmacol. 2023; 15:13-26.

PMID: 36699694 PMC: 9869698. DOI: 10.2147/JEP.S382895.


References
1.
Fraser E . Long term respiratory complications of covid-19. BMJ. 2020; 370:m3001. DOI: 10.1136/bmj.m3001. View

2.
Tran T, Malainer C, Schwaiger S, Atanasov A, Heiss E, Dirsch V . NF-κB inhibitors from Eurycoma longifolia. J Nat Prod. 2014; 77(3):483-8. PMC: 3971761. DOI: 10.1021/np400701k. View

3.
Mishra A, Dave N . Neem oil poisoning: Case report of an adult with toxic encephalopathy. Indian J Crit Care Med. 2013; 17(5):321-2. PMC: 3841499. DOI: 10.4103/0972-5229.120330. View

4.
Paterson R, Brown R, Benjamin L, Nortley R, Wiethoff S, Bharucha T . The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020; 143(10):3104-3120. PMC: 7454352. DOI: 10.1093/brain/awaa240. View

5.
Im E, Ae A, Bn U, Po U . IMMUNO-MODULATORY PROPERTIES OF PREBIOTICS EXTRACTED FROM . Afr J Tradit Complement Altern Med. 2017; 13(6):11-17. PMC: 5412181. DOI: 10.21010/ajtcam.v13i6.3. View